Phase 3 Bipolar Disorder Trial, Recruiting NCT06951711 Sponsor: Bristol-Myers Squibb Condition: Bipolar Disorder
Back to Bipolar Disorder

Phase 3 Bipolar Disorder Trial, Recruiting

NCT06951711
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been formally diagnosed with Bipolar I disorder through a thorough psychiatric assessment.
  • People who are currently experiencing an acute episode of mania or mania with mixed features that has lasted 3 weeks or less.
  • People whose symptoms are severe enough to require a hospital stay.
  • People who have stopped taking all psychiatric medications within the 14 days before starting the study drug.
  • People whose mania symptoms score at or above a certain level (≥20) on a standard rating scale called the Young Mania Rating Scale, measured at two separate points before the trial begins.
  • People whose overall illness severity scores at or above a certain level (≥4) on a standard clinical rating tool called the CGI-BP, measured at two separate points before the trial begins.

Who may not be able to join:

  • People who have been diagnosed with certain other mental health conditions in the past 12 months — including Bipolar II disorder, borderline personality disorder, major depressive disorder, or a primary psychotic disorder — or who have experienced a Bipolar I depressive episode in the past 3 months. Mild anxiety disorders are an exception to this rule.
  • People whose Bipolar I disorder involves rapid cycling, meaning four or more distinct mood episodes within one year.
  • People who have had a moderate to severe substance use disorder (other than tobacco) in the past 12 months, or whose urine or alcohol testing shows current substance use.
  • People assessed as being at risk of suicidal behaviour at the time of screening or the baseline visit, based on clinical judgement and a standardised suicide risk scale.
  • People who have cirrhosis, liver cancer, or clinically significant liver disease based on liver function test results.
  • There are additional criteria not listed here that the trial site will assess (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
13 June 2025
Est. completion
2 November 2026

Where this trial is recruiting

🇨🇳 China 🇭🇷 Croatia 🇮🇳 India 🇮🇱 Israel 🇮🇹 Italy 🇷🇴 Romania 🇸🇰 Slovakia 🇪🇸 Spain 🇸🇪 Sweden 🇺🇦 Ukraine 🇺🇸 United States

Primary endpoints

Change from baseline in Young Mania Rating Scale (YMRS) score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov